Cevostamab Becomes More Efficacious With Double Step-Up Dosing in Pretreated R/R Myeloma
December 15th 2021Patients with heavily pretreated relapsed/refractory multiple myeloma achieved promising benefit in terms of cytokine release syndrome mitigation via double cycle 1 step-up dosing for cevostamab.
Treatment With Tafasitamab, Lenalidomide, and R-CHOP Yields Promising Activity in Untreated DLBCL
December 14th 2021Patients with previously untreated diffuse large B-cell lymphoma experienced promising responses after being treated with tafasitamab-cxix and lenalidomide plus rituximab, cyclophosphamide, doxorubicin, vincristin, and prednisone.
More Favorable Safety Profile of Acalabrutinib Vs Ibrutinib Validated for CLL
December 14th 2021A post-hoc analysis of a phase 3 trial presented at 2021 ASH indicate that acalabrutinib may be favorable in terms of toxic burden and cardiovascular-related events when compared against ibrutinib for treating chronic lymphocytic leukemia.
Standard of Care More Effective in Reducing MRD Than Ibrutinib Plus Venetoclax for CLL
December 14th 2021Standard of care treatment was superior to the combination of ibrutinib plus venetoclax in terms of decreasing minimal residual disease for previously untreated patients with chronic lymphocytic leukemia.
Adding Ibrutinib to FCR Combo Shows Promise as Time-Limited Therapy in Younger Patients With CLL
December 14th 2021The time-limited combination of ibrutinib plus chemoimmunotherapy in younger fit patients with chronic lymphocytic leukemia increased the rate of complete responses with bone marrow undetectable minimal residual disease, regardless of IGHV mutation, according to long-term follow-up data.